Twitter Beğeni Hilesi

Hospitalised patients with cirrhosis and AKI presenting with AH had higher 90-day mortality than those without AH, but this may have been driven by higher MELD-Na rather than AH itself roypounder.apt Kavish Patidar onlinelibrary.wiley.com/doi/10.1111/ap…

Compared with PNPLA3 noncarriers without heavy alcohol consumption, HCC risk was 2.65-fold higher (HR, 2.65; 95% CI, 1.20-5.86) for carriers who had current heavy alcohol consumption. Aaron Thrift Gastroenterology Fasiha Kanwal Hashem el- Serag cghjournal.org/article/S1542-…

A how to for multidisciplinary clinics in hepatology doi.org/10.1097/hep.00… in HEPATOLOGY Journal Anjana Pillai

New content online: Consequences of bathroom restriction on transgender individuals with gastrointestinal conditions in the United States dlvr.it/TCjpCN

Thank you for the shout out Elliot Tapper -something I’ve been wanting to write up for some time and just needed to find the right people to weigh in with their expertise! Liver/Intestinal Community of Practice - AST HEPATOLOGY Journal

🚨Labor Day Sale Alert🚨 If you are interested in learning #DEI issues in #transplant with me and other⭐️speakers, including Norah Terrault SandyFeng kym watt Julie Heimbach Lauren Nephew MD, MSCE, please join us on 9/13-14 at the very first #DEIinTransplant2024 in Toronto 🇨🇦!

We're having an MOC party and you're all invited! Pediatric liver transplant recipients are not just young adults by Jennifer Vittorio Lindsay Y King Nancy Yang journals.lww.com/lt/abstract/20…

Incredibly proud of American Gastroenterological Association (AGA) #YoungScholar Cass Dale Condray for raising awareness on impact of #bathroombans on transgender individuals with GI conditions. Rainbows in Gastro Kira Newman, MD, PhD Mayo Clinic Gastroenterology & Hepatology UMichGIHep-Fellowship ACG Crohn's & Colitis Foundation - Minnesota/Dakotas Crohn's & Colitis Foundation

Have you seen our 𝐀.𝐈. & 𝐓𝐫𝐚𝐧𝐬𝐩𝐥𝐚𝐧𝐭𝐚𝐭𝐢𝐨𝐧 sessions? Explore this webinar and more from the series on our YouTube channel. youtu.be/FSh6osf0EYc?si…

Time for Transplant Tuesday! 🌟🔥 Prior or updated MELD for alc hep prognostication? 🧐 Al-Kharagouli et al showed that updated MELD measurements had a strong predictive value for death/transplant, in this paper published in Hepatology Communications. ✨ journals.lww.com/hepcomm/fullte…

👉A great 📚 to review "Evaluation and management strategies of portal vein thrombosis in cirrhosis" Gastroenterology American Gastroenterological Association (AGA) CGH TIGE Gastro Hep Advances AASLD Liver Fellow Network #GITwitter #livertwitter #MedTwitter gastrojournal.org/article/S0016-…

Let’s talk about S-E-X! Today is World #SexualHealth Day. If you choose to have sex: 💞 Ensure it is consensual 💞 Have fun 💞 Be safe bit.ly/45OMvZb

>50% #cirrhosis pts w cognitive issues🚫have #hepaticencephalopathy & #microbiome profile differs but is this ready to use? ✅machine learning paper pubmed.ncbi.nlm.nih.gov/39189586 >300 pts➡️💩>80% HE specificity, ⬆️stakeholder acceptance, 3 ctr validation➡️changed HE diagnosis in >40%

Thank you, APAMSA McGovern Med School🙏, for inviting me to give one of my favorite talks-#HBV I am so happy to share my passion with a room full of young & enthusiastic med students🧑‍🎓👩‍🎓 ! The future of medicine is bright! 🌞 And YES you can🚶to another medical school to give a talk

The Texas Collaborative Center for Hepatocellular Cancer (TeCH) hosted its 4th Annual HCC Symposium at our McNair campus! Special thanks to keynote speaker Dr. Sudhir Srivastava, BCM faculty, and Drs. Hashem El-Serag, Fasiha Kanwal who made the event a success! 🤩 #BCMDoM

Exciting news! Elafibranor is now available for the treatment of non-responding #PBC patients. Our latest review of the data from the New England Journal of Medicine highlights the significant potential of this PPAR agonist ⁦Daniela Goyes, MD⁩ practiceupdate.com/content/effica…

Excited to talk about updates in Liver Transplantation for Alcohol associated Liver Disease in October! Come join us to learn about what’s on the horizon and what Duke has done to change our policies in the past 2 years. Duke GI

Explore Your Path at #TLM24 Are you ready to navigate #hepatology like never before? Our Journey Maps are here to guide you! These maps offer #LiverMeeting attendees a personalized experience tailored to their interests. View them now. aasld.org/the-liver-meet…

Our own #jmvierling Primary biliary cholangitis - The Lancet Seminar The Lancet thelancet.com/journals/lance…

Are you thinking of designing clinical trials in alc-associated liver disease? Read this consensus Nature Reviews Gastroenterology & Hepatology nature.com/articles/s4157…